In the trial by Libster and coworkers,15 high-titer CP administered within 72 hours from the onset of mild COVID-19 reduced the progression of the disease in older adults (severe respiratory failure occurred in 16% of patients treated with CP vs 31% of those who received placebo; P = .03). Here, CP is linked to respiratory failure.